Evidence map›Paper›PMID 32322913›Full record

ArticleCancer chemotherapy and pharmacology2020

Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.

Yoshiaki Fujimoto, Ryota Nakanishi, Mamoru Nukatsuka, Kazuaki Matsuoka, Koji Ando, Takeshi Wakasa, Hiroyuki Kitao, Eiji Oki, Yoshihiko Maehara, Masaki Mori

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Biomarkers of Trifluridine-Tipiracil Efficacy.Journal of clinical medicine · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yoshiaki FujimotoDepartment of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryota NakanishiDepartment of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Mamoru NukatsukaTranslational Research Laboratory, Taiho Pharmaceutical Co. Ltd., Tokushima, Japan.
Kazuaki MatsuokaTranslational Research Laboratory, Taiho Pharmaceutical Co. Ltd., Tokushima, Japan.
Koji AndoDepartment of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takeshi WakasaTranslational Research Laboratory, Taiho Pharmaceutical Co. Ltd., Tokushima, Japan.
Hiroyuki KitaoDepartment of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan. hkitao@phar.kyushu-u.ac.jp.
Eiji OkiDepartment of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshihiko MaeharaDepartment of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Masaki MoriDepartment of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kyushu University · JPTaiho Pharmaceutical (Japan) · JPKyushu Central Hospital of the Mutual Aid Association of Public School Teachers · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTrifluridine (FTD) is the active component of the nucleoside chemotherapeutic drug trifluridine/tipiracil (FTD/TPI), which is approved worldwide for the treatment of patients with metastatic gastrointestinal cancer. FTD exerts cytotoxic effects via its incorporation into DNA, but FTD has not been detected in the tumor specimens of patients. The purpose of this study was to detect FTD in tumors resected from metastatic colorectal cancer (mCRC) patients who were administered FTD/TPI. Another purpose was to investigate the turnover rate of FTD in tumors and bone marrow in a mouse model.

methodsTumors and normal tissue specimens were obtained from mCRC patients who were administered FTD/TPI or placebo at Kyushu University Hospital. Tumors and bone marrow were resected from mice with peritoneal dissemination treated with FTD/TPI. To detect and quantitate FTD incorporated into DNA, immunohistochemical staining of paraffin-embedded specimens (IHC-p staining) and slot-blot analysis of DNA purified from these tissues were performed using an anti-BrdU antibody. IHC-p staining of proliferation and apoptosis markers was also performed.

resultsFTD was detected in metastatic tumors obtained from mCRC patients who were administered FTD/TPI, but who had discontinued the treatment several weeks before surgery. In a peritoneal dissemination mouse model, FTD was still detected in tumors 13 days after the cessation of FTD/TPI treatment, but had disappeared from bone marrow within 6 days.

conclusionThese results indicate that FTD persists longer in tumors than in bone marrow, which may cause a sustained antitumor effect with tolerable hematotoxicity.

Indexed as

AnimalsApoptosisCell ProliferationColorectal NeoplasmsDrug CombinationsHumansLiver NeoplasmsMiceMice, Inbred BALB CMice, NudePrognosisPyrrolidinesThymineTrifluridineTumor Cells, CulturedXenograft Model Antitumor AssaysDrug CombinationsPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationAnti-BrdU antibodyLiver metastasisPeritoneal disseminationTAS-102)Trifluridine (FTD)Trifluridine/tipiracil (FTD/TPI

Identifiers

PMID32322913
OpenAlexW3019573140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.